MOTS-CWhat the studies show

The paper in Cell Metabolism that introduced MOTS-c gave it to mice daily by injection. Mice on a high-fat diet that received the peptide gained far less weight and fat than mice on the same diet given saline, without eating less, and the insulin resistance that diet normally causes did not develop ¹. In older mice, which become insulin resistant with age, the peptide prevented that too, and a one-week course in young mice improved how quickly they cleared glucose ¹. The authors found the effect concentrated in skeletal muscle, where glucose uptake rose, and traced it to AMPK: block that pathway and the effect disappeared. They also reported that MOTS-c levels in muscle and blood fell with age in mice ¹.

A 2018 follow-up from the same group found that under metabolic stress — glucose starvation, oxidative damage — MOTS-c moves from the mitochondria into the nucleus and changes the activity of stress-response genes there, which is a rare thing for a mitochondrial product to do ².

The human data arrived in 2021 in Nature Communications. Ten healthy, sedentary young men did a bout of cycling, and muscle biopsies and blood samples taken before, during and after showed MOTS-c rising sharply in muscle during exercise and more modestly in plasma, then falling back after a rest period ³. In the same paper, mice given MOTS-c ran further on a treadmill, and old mice started on the peptide late in life kept more of their physical capacity than untreated old mice ³. The exercise finding is an observation of what the body does on its own; the running findings are in mice.

There is one piece of human genetic evidence. A variant in the MOTS-c sequence that swaps one amino acid, found in a share of people of East Asian ancestry, was associated with a higher rate of type 2 diabetes in Japanese men in a 2021 study, and the variant peptide was less active in cells ⁴. That does not show what giving the peptide would do, but it is the kind of result that suggests the natural peptide matters in people.

No placebo-controlled trial of MOTS-c in people has been published. The peptide does not survive long in blood, and whether an injected dose reaches muscle at useful levels in a human is not established. MOTS-c is not an approved drug anywhere. Everything that circulates about MOTS-c as "exercise in a syringe" is extrapolation from the mouse work above, from one research group, and the ten-person exercise study measured what the body makes on its own, not what happens when the peptide is given.